不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
持续性 COVID-19：一例免疫缺陷患者的病例报告及文献综述
英文原题：Persistent COVID-19: A Case Report of an Immunocompromised Patient and a Literature Review.
查看英文原题
Persistent COVID-19: A Case Report of an Immunocompromised Patient and a Literature Review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
研究 SARS-CoV-2 在免疫功能低下且患有不明原因肺炎患者的痰/支气管肺泡灌洗样本中的 RT-PCR 结果可能具有重要意义。
研究思路结论见上方概要
背景
免疫功能低下患者可表现为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）持续排毒和症状持续，称为持续性COVID-19。病例报告：我们报告一例接受套细胞淋巴瘤治疗并存在B细胞耗竭的免疫功能低下患者。该患者发展为持续性COVID-19，仅痰液和支气管肺泡灌洗液中的实时聚合酶链反应（RT-PCR）检测呈阳性，且至少持续112天。该患者经SARS-CoV-2恢复期血浆治疗成功。
展开英文摘要原文
INTRODUCTION: Immunocompromised patients can show prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and persistent symptoms, which is called persistent COVID-19. CASE PRESENTATION: We report a case of an immunocompromised patient who was treated for mantle cell lymphoma and was suffering from B-cell depletion. The patient developed persistent COVID-19, which was confirmed by real-time polymerase chain reaction (RT-PCR) tests in only sputum and bronchoalveolar fluid which remained positive for at least 112 days. The patient was successfully treated with SARS-CoV-2 convalescent plasma. CONCLUSION: It could be of interest to investigate the RT-PCR results of SARS-CoV-2 in sputum/bronchoalveolar lavage samples from immunocompromised patients with unexplained pneumonia.
论文信息
- 作者
- Bekkaoui S、Venton G、Bretelle F、Garrido V、Chabbert V、Gayet S、Dalmas P、Tichadou A
- 单位
- Internal Medicine and Therapeutics Department, CHU La Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.France
- 文献类型
- 病例报告 · 综述
- 期刊
- Acta haematologica2024
- 原文标识
- PubMed 38359806 · DOI 10.1159/000537793